Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Humanwell Healthcare (Group) Co's enterprise value is ¥35,980 Mil.
Humanwell Healthcare (Group) Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3,412 Mil. Therefore, Humanwell Healthcare (Group) Co's EV-to-EBITDA for today is 10.54.
The historical rank and industry rank for Humanwell Healthcare (Group) Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600079'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.03 Med: 12.88 Max: 24.7
Current: 10.61
During the past 13 years, the highest EV-to-EBITDA of Humanwell Healthcare (Group) Co was 24.70. The lowest was -58.03. And the median was 12.88.
SHSE:600079's EV-to-EBITDA is ranked better than 59.26% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs SHSE:600079: 10.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Humanwell Healthcare (Group) Co (SHSE:600079) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Humanwell Healthcare (Group) Co's PE Ratio (TTM) for today is calculated as:
Humanwell Healthcare (Group) Co's share price for today is ¥18.05.
Humanwell Healthcare (Group) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Humanwell Healthcare (Group) Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanwell Healthcare (Group) Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Humanwell Healthcare (Group) Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Humanwell Healthcare (Group) Co's EV-to-EBITDA falls into.
Humanwell Healthcare (Group) Co's current Enterprise Value is ¥35,980 Mil.
Humanwell Healthcare (Group) Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,412 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co (SHSE:600079) has a EV-to-EBITDA of 10.54 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Humanwell Healthcare (Group) Co. This is 18% below median its historical median of 12.88. According to the industry distribution chart, Humanwell Healthcare (Group) Co ranks #299 out of 734 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is Humanwell Healthcare (Group) Co's EV-to-EBITDA too high?
Humanwell Healthcare (Group) Co's current EV-to-EBITDA of 10.54 is 18% below median its 10-year median of 12.88. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Humanwell Healthcare (Group) Co's value of 10.54 is 20.9% below this industry median. Based on the distribution chart, Humanwell Healthcare (Group) Co ranks #299 out of 734 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Humanwell Healthcare (Group) Co ranks #299 out of 734 companies for EV-to-EBITDA. This puts Humanwell Healthcare (Group) Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.33. Humanwell Healthcare (Group) Co's value of 10.54 is 20.9% below this benchmark. While the company's 10-year median is 12.88 vs. the industry median of 13.33, Humanwell Healthcare (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humanwell Healthcare (Group) Co's current EV-to-EBITDA of 10.54 is 20.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Humanwell Healthcare (Group) Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humanwell Healthcare (Group) Co's current EV-to-EBITDA is 10.54, which is 18% below median its own 10-year median of 12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.11, compared to a current price of ¥18.05 — trading 18.4% below its estimated fair value. The current EV-to-EBITDA is 10.54, which is 18% below median its 10-year median of 12.88 and 20.9% below the Drug Manufacturers industry median of 13.33. Humanwell Healthcare (Group) Co's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current EV-to-EBITDA is 10.54 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥18.05 is trading 18.4% below its estimated GF Value™ of ¥22.11.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
EV-to-EBITDA: 10.54 (18% below median its 10-year median of 12.88)
GF Value™: ¥22.11 vs. price of ¥18.05 (18.4% below fair value)
Industry Position: 20.9% below the Drug Manufacturers median (#299 of 734)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
64GF Score
Get the complete analysis for SHSE:600079
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
